Amphastar P (AMPH) - Total Liabilities
Based on the latest financial reports, Amphastar P (AMPH) has total liabilities worth $840.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amphastar P cash flow conversion to assess how effectively this company generates cash.
Amphastar P - Total Liabilities Trend (2012–2025)
This chart illustrates how Amphastar P's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Amphastar P to evaluate the company's liquid asset resilience ratio.
Amphastar P Competitors by Total Liabilities
The table below lists competitors of Amphastar P ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Catalyst Metals Ltd
AU:CYL
|
Australia | AU$195.72 Million |
|
Daktronics Inc
NASDAQ:DAKT
|
USA | $252.64 Million |
|
Fujian Guanfu Modern Household Wares Co Ltd
SHE:002102
|
China | CN¥3.28 Billion |
|
Hartalega Holdings Bhd
KLSE:5168
|
Malaysia | RM409.55 Million |
|
Zhejiang Yuejian Intelligent Equipment Co Ltd
SHG:603095
|
China | CN¥661.41 Million |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
USA | $6.98 Billion |
|
Evolv Technologies Holdings Inc
NASDAQ:EVLV
|
USA | $202.05 Million |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥1.62 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Amphastar P's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AMPH stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amphastar P's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amphastar P (2012–2025)
The table below shows the annual total liabilities of Amphastar P from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $840.49 Million | -0.55% |
| 2024-12-31 | $845.17 Million | -3.24% |
| 2023-12-31 | $873.49 Million | +309.46% |
| 2022-12-31 | $213.33 Million | -5.61% |
| 2021-12-31 | $226.01 Million | +23.83% |
| 2020-12-31 | $182.51 Million | +14.47% |
| 2019-12-31 | $159.44 Million | +6.86% |
| 2018-12-31 | $149.20 Million | +27.16% |
| 2017-12-31 | $117.34 Million | +19.14% |
| 2016-12-31 | $98.48 Million | +4.08% |
| 2015-12-31 | $94.63 Million | -11.98% |
| 2014-12-31 | $107.51 Million | +23.29% |
| 2013-12-31 | $87.20 Million | +3.77% |
| 2012-12-31 | $84.04 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more